Incorporating the Patient Voice: How Patient Insights Drive Trial Design and Outcome Measures in Schizophrenia Research

Schizophrenia is a complex and challenging condition that significantly impacts patients’ lives. Traditional clinical trial designs often fail to capture the full spectrum of patient experiences and outcomes. By incorporating patient insights, we can develop more patient-centric trials that improve recruitment and retention and ensure that the outcomes measured are meaningful to those living with the condition.

Join us for an insightful webinar that delves into the critical role of patient insights in optimizing clinical trial design and outcome measures for schizophrenia studies. Moderated by Dr. Mohit Verma, global therapeutic area head of psychiatry at Parexel, this session will feature leading experts from Parexel’s feasibility and clinical operations teams.

Key Topics:

  • Changing regulatory landscape: Insights into recent interactions with regulatory agencies and implications for advancing novel therapies.
  • Patient insights in trial design: Best practices for engaging patients and caregivers to inform protocol design, eligibility criteria, and recruitment/retention strategies.
  • Innovative outcome measures: Development and validation of patient-reported outcomes and other endpoints, including new digital tools for assessing cognitive impairment.
  • Future directions: Impact of global events on trial recruitment, precision medicine approaches, and strategies for reaching targeted patient populations.

Speakers:

Moderator: Mohit Verma, M.D., Global Therapeutic Area Head, Psychiatry, Parexel
Panelists:

  • Jaime Roberts, Associate Director, Feasibility Strategy, Parexel
  • Katja Rudell, Senior Director, Clinical Outcomes Assessment, Parexel

Who Should Attend: This webinar is essential for sponsors, researchers, regulators, and drug developers working on innovative therapies for schizophrenia. Gain expert perspectives on navigating the complex landscape of schizophrenia clinical trials and drug development.
 

Return to Insights Center